F OR MANY YEARS, investigators have tried to define a male counterpart to the female menopause (1, 2), and after much debate for the past 2 decades, it has become clear that levels ,of testosterone decrease slowly in men after the age of 40 yr (3). Further, the fall is greater in the free fraction of testosterone because of a rise in sex hormone-binding globulin (4).
Although considerable lowering of male hormone has been associated with decreased libido and decreased ability to achieve spontaneous erections (5,6), the minimum level of testosterone needed to maintain it is not really known. Further, exogenous testosterone showed an improvement in libido and nocturnal penile tumescence in younger hypogonadal men (7-9) but did not have similar effects in eugonadal men (10).
Organic impotence increases steadily in men more than 50 yr of age and can be multifactorial (111, and a number of these men have been found to have low or low normal androgens. After careful study, when a cause and effect was not found between the low testosterone levels and sexual dysfunction, the researchers (12) suggested that the two conditions should be evaluated separately because they are separate conditions. When the benefit of elevating the slightly low testosterone levels in elderly men was studied by using exogenous testosterone, it raised the hematocrit as well as the prostatespecific antigen level, but positive changes in sexual function were not mentioned (13).
We (14) previously reported a group of men examined for impotence, who, along with mildly low testosterone levels, did not have elevated gonadotropin levels and in whom endogenous testosterone levels could be restored to the normal range by the use of clomiphene citrate. Our current work is designed to study the effect of raising the levels of circulating testosterone without suppressing the hypothalamicpituitary axis on libido and erectile function. During a recent consensus conference it was decided that such studies were needed in the area of sexual function in aging men (15).
Subjects and Methods

Subject selection
Men were considered candidates for this study when they had the complaint of erectile dysfunction for 6 or more months and low serum free testosterone levels and normal (or unstimulated) serum gonadotropin levels in an early (0800-1000 h) sample. An overlap was permitted in the normal range for serum total testosterone; although the normal range was greater than 250 ng/dL, patients were accepted for study when the level was equal to or less than 275 ng/dL. This was to compensate for the higher sex hormone-binding globulin level seen in older men. 
Results
Seventeen men, with a median age of 60.5 yr (range, 42-71 yr), completed the study. The detailed baseline hormone data are listed in Table 2 .
GnRH stimulation
Stimulation of pituitary function in the men (n = 17) with GnRH showed a statistically significant rise in LH and FSH at 30 and 60 min. The LH level rose from 6.67 ? 1.53 mIU/mL (&SD) at baseline to 21.61 + 7.19 mIU/mL at 30 min (P < 0.001) and 19.50 + 6.62 mIU/mL at 60 min (P < 0.001) after stimulation. The FSH level rose from 3.22 2 1.40 mIU/mL (*SD) at baseline to 7.61 2 3.31 mIU/mL at 30 min (P < 0.001) and 7.50 k 3.13 mIU/mL at 60 min (P < 0.001) after stimulation (significance determined by analysis of variance with repeated measures). Clomiphene challenge test
The integrity of the entire hypothalamic-pituitary-testicular axis was tested with the clomiphene challenge test and showed a significant response. LH rose from 6.41 ? 1.50 mIU/mL on day 0 to 9.23 ? 2.75 mIU/mL on day 7 (P < 0.001) and 9.71 2 2.69 mIU/mL on day 10 (P < 0.001) after stimulation. FSH rose from 3.06 2 1.09 mIU/mL on day 0 to 5.06 t 2.46 mIU/mL on day 7 (P < 0.001) and to 5.82 2 2.67 mIU/mL on day 10 (P < 0.001) after stimulation (significance determined by analysis of variance with repeated measures). Total testosterone rose from 262.2 t-75.8 ng/dL on day 0 to 389.2 ? 94.9 ng/dL on day 7 (P < 0.001) to 480.7 + 129.7 ng/dL on day 10 (P < 0.001) after stimulation (analysis of variance with repeated measures). The free testosterone level rose from 10.0 2 2.5 pg/mL on day 0 to 13.9 -C 3.9 pg/mL on day 7 (P < 0.001) to 16.3 t 3.8 pg/mL on day 10 (P < 0.001) after stimulation (significance determined by analysis of variance with repeated measures).
Treatment phase
The treatment phase showed a significant response for clomiphene over the placebo as well as over the baseline. This was true for all hormones tested after both the first and second months of therapy (Fig. 1) . Also, the values for all hormones did not significantly differ between the first and second months of therapy. The serum level of LH rose from 6.4 2 1.5 to 10.3 2 3.5 mIU/mL (-CSD) at 1 month and 10.2 + 3.1 mIU/mL at 2 months (P < 0.01). The level of serum FSH likewise rose from 3.4 5 1.4 to 5.6 ? 2.7 mIU/mL at 1 month and was at 5.6 t 3.4 mIU/mL at 2 months (P < 0.05). The level of serum total testosterone was also significant, rising from 237.6 ? 38.3 to 549.6 t 131.9 ng/dL at 1 month and to 527.0 ? 149.9 ng/dL at 2 months (P < 0.01). The level of serum free testosterone rose in parallel from 10.0 +-2.5 to 19.2 ? 3.9 pg/mL at 1 month and 17.8 ? 5.0 pg/mL at 2 months (P < 0.01).
Questionnaires and nocturnal monitoring
The responses to questionnaires (Table 3) revealed no significant changes in a variety of parameters related to sexual function as viewed subjectively by the patient. 2 analysis of the patients' response, when they were asked whether they thought that drug A or drug B was the active drug, confirmed that the subjects were not able to distinguish correctly. Objective monitoring of nocturnal tumescence and rigidity with the RigiScan also did not show any significant change during any phase of treatment (Table 4) .
Secondary analysis
In secondary analysis of the data, when the patients were separated by the median age of the sample, the mean ages of the two groups were 53.0 yr (n = 8) and 66.4 yr (n = 9). Isolated parameters were found that seemed to improve with higher testosterone levels in the younger group. This was true of both nocturnal penile tumescence and rigidity testing as well as from the results of the questionnaires (Table 5) .
In a further secondary analysis, the patient population was separated by men with (n = 9) or without (n = 8) diabetes, hypertension, or both (Table 6 ). There was no significant age difference, nor was there any difference in the basal hormone levels. The men without diabetes and hypertension showed some limited significant sexual improvement in both objective and subjective measurements. The stimulated total testosterone level was not different in the two groups, but the free testosterone level showed a trend toward significance in men without diabetes or hypertension. 
Discussion
Sexual function declines with age, and, as noted by Martin (161, even in healthy men with several partners, the frequency of sexual intercourse declined to nearly nonexistent levels in a large number of men more than 65 yr old. On a similar note, but in a less permissive society, Kinsey and colleagues (17) provided a reason for this decline when they reported an increasing prevalence of impotence with advancing age (~2% until age 40 yr, 6.7% by age 55 yr, and increasing to 24% by age 70 yr). Recently, the communitybased random sample of noninstitutionalized men provided similar data, reporting that the prevalence of total impotence tripled from 5% to 15% between 40 and 70 yr of age. More recently, it was thought that as many as 52% of men more than 40 yr of age had some degree of sexual difficulty (18).
A slow but steady decline in the level of circulating androgens is known to occur in aging men. Declining levels of total testosterone (191, free testosterone (41, and bioavailable testosterone (20) have suggested decreasing testicular func- (26) have supported the impact of aging on the hypothalamic-pituitary axis, suggesting that age in men affects the entire hypothalamicgonadotropin-Leydig cell axis (27). Armed with the facts of hypogonadism and decrease in sexual activity and with the prior knowledge that sexual behavior and libido are affected by circulating androgens (28-301, causality to the declining androgens for decreased sexual function was assigned by association (16). Closer examination of the relationship between hypogonadism and impotence suggested that although hypogonadism and impotence are commonly associated, they may be independent problems associated with aging (12).
The conclusion found support when reduced androgen levels were restored by exogenously administered testosterone but did not seem to restore sexual capabilities (9, 10, 28) . Despite this evidence, testosterone replacement in older men is practiced routinely when a decline in sexual function is reported. These practices found support in the lay literature and may expose elderly men to prostate stimulation and other potentially undesired effects (13).
Secondary hypogonadism, as defined in our patients, refers to a low free testosterone level that is not compensated for by an increase in LH secretion. Our work, reported in this article, helps to nullify the idea of using testosterone indiscriminately in an aging population with the explicit purpose of restoring sexual function. Whereas previous attempts to use exogenous testosterone did not help, we have shown that elevated endogenous testosterone levels did not fare any better. To assess subjective sexual performance, we questioned the patients by using focused questionnaires.
To judge objective sexual capability, we used nocturnal penile tumescence and rigidity monitoring and, instead of using exogenous testosterone, which can suppress the hypothalamic-pituitary axis, we used clomiphene citrate in a population of 17 impotent men with secondary hypogonadism.
Clomiphene citrate, as we (14) reported previously in this type of population, elevates circulating androgen levels by stimulating the Leydig cells indirectly by means of stimulating GnRH production from the hypothalamus. Despite the significant rise in androgen levels over a moderate period of time (2 months), no clear improvement occurred in the subjects' self-reported sexual behavior or their objective nocturnal penile tumescence and rigidity measurements.
Questioning the patients in the office at each stage of the double blind, placebo-controlled trial revealed that the patients were unable to distinguish between the active and inactive drug.
If, however, our treatment group was divided by the median age of the population, the younger men's responses became significant compared with those of the older men. The same was somewhat true when the responses of men without hypertension or diabetes were compared with those of men who had these conditions. Although the small numbers of men prevent sweeping conclusions, further studies would seem warranted. Supporting our observations, Gray et al. (31) and Handelsman (32) also showed that older men with ill health had lower testosterone levels than their healthy age-matched counterparts. Lower free testosterone levels were shown in men with hypertension when they were taking several different antihypertensive medications (32, 33) . It is also possible, and probable, that many conditions, especially diabetes and hypertension, cause erectile dysfunction without any effect on the hormone levels, because of direct neural and vascular damage.
In certain circumstances, especially in younger patients and those who do not manifest one or more chronic diseases, i.e., diabetes and hypertension, a short course of clomiphene citrate may be tried for several months when the free testosterone level is seen to be lowered. It must also be remembered that 16% of our initial study group, who also had slightly low free testosterone levels, had completely normal results on nocturnal penile tumescence testing consistent with psychological impotence. Thus, the baseline status of the patient must be ascertained accurately either by history or nocturnal tumescence testing.
Although certain selected patients may respond to hormonal augmentation, the clear message seems to be that sexual dysfunction and associated low testosterone levels are not causally related in all patients and that androgens should not be given indiscriminately to every man over a predetermined age.
